Nurix Therapeutics: Q3 2026 earnings
Results from July 9, 2026
Nurix Therapeutics (NRIX) reported its Q3 2026 financial results after market close on July 9, 2026. The company reported revenue of 9 million USD and an EPS of -0.81 USD, missing the analyst estimate of -0.72 USD by 12.1%. Following the release, the stock price fell by 7.65%.
Generated automatically from our data — as of July 11, 2026
Estimate (EPS): -0.72 USD
Reported (EPS): -0.81 USD
Price reaction: -7.7%